Titan Medical Inc. Appoints Dr. Bruce Wolff to the Board of Directors
March 11 2014 - 4:03PM
Marketwired
Titan Medical Inc. Appoints Dr. Bruce Wolff to the Board of
Directors
TORONTO, ONTARIO--(Marketwired - Mar 11, 2014) - Titan Medical
Inc. ("Titan" or the "Company") (TSX-VENTURE:TMD)(OTCQX:TITXF) is
pleased to announce that Dr. Bruce Giles Wolff, M. D., Professor of
Surgery, Mayo Clinic College of Medicine and Emeritus Chair of the
Division of Colon & Rectal Surgery, Mayo Clinic - Rochester,
Minn., has been appointed to the Board of Directors. Dr. Wolff has
been a member of the Mayo Clinic's Surgical Administrative
Committee since 2006. Dr. Wolff is a former President of the
American Society of Colon and Rectal Surgeons, a former Director
and President of the American Board of Colon and Rectal Surgery,
and a former Vice President and Director of the Foundation for
Surgical Fellowships. Dr. Wolff has written extensively on colon
and rectal surgery issues in almost 300 articles for publications
such as The American Journal of Surgery, the Canadian Journal of
Surgery, the World Journal of Surgery, Mayo Clinic Proceedings, the
America Surgeon, the Journal of Gastrointestinal Surgery, Diseases
of the Colon & Rectum, Annals of Surgery and the British
Journal of Surgery.
Dr. Wolff received
his M.D. from Duke University School of Medicine and interned and
completed his residency at the New York Hospital Cornell Medical
Centre. He received a fellowship from the Mayo Clinic in 1981-82
and since then he has taught and practiced medicine at the Mayo
Clinic.
"I am delighted that
such a renowned medical professional such as Dr. Wolff has agreed
to be a Director on Titan's Board of Directors. He has a wealth of
expertise and experience in the colon and rectal surgery field
which will be of great benefit to Titan" stated Titan CEO John
Hargrove.
About Titan Medical
Inc.
Titan Medical Inc.
is a Canadian public company focused on the design and development
of a robotic surgical system for application in minimally invasive
surgery ("MIS"). The Company's Single Port Orifice Robotic
Technology, SPORT™ Surgical System, currently under development,
comprises a surgeon-controlled robotic platform that includes a 3D
vision system and interactive instruments for performing MIS
procedures, and a surgeon workstation that provides the surgeon
with an interface to the robotic platform for controlling the
interactive instruments and providing a 3D endoscopic view of
inside a patient's body during MIS procedures. The SPORT™ Surgical
System is being designed to expand robotic surgery into areas of
surgical specialties and simple and complex procedures that are
currently under-serviced, and to allow surgeons to perform
procedures within small to medium size surgical spaces such as
general surgery and cholecystectomy. For more information, visit
the Company's website at www.titanmedicalinc.com.
Forward-Looking
Statements
This news release
contains "forward-looking statements" which reflect the current
expectations of management of the Company's future growth, results
of operations, performance and business prospects and
opportunities. Wherever possible, words such as "may", "would",
"could", "will", "anticipate", "believe", "plan", "expect",
"intend", "estimate", "potential for" and similar expressions have
been used to identify these forward-looking statements. These
statements reflect management's current beliefs with respect to
future events and are based on information currently available to
management. Forward-looking statements involve significant risks,
uncertainties and assumptions. Many factors could cause the
Company's actual results, performance or achievements to be
materially different from any future results, performance or
achievements that may be expressed or implied by such
forward-looking statements, including, without limitation, those
listed in the "Risk Factors" section of the Company's Annual
Information Form dated April 10, 2013 (which may be viewed at
www.sedar.com). Should one or more of these risks or uncertainties
materialize, or should assumptions underlying the forward-looking
statements prove incorrect, actual results, performance or
achievements may vary materially from those expressed or implied by
the forward-looking statements contained in this news release.
These factors should be considered carefully and prospective
investors should not place undue reliance on the forward-looking
statements. Although the forward-looking statements contained in
the news release are based upon what management currently believes
to be reasonable assumptions, the Company cannot assure prospective
investors that actual results, performance or achievements will be
consistent with these forward-looking statements.
Neither TSX Venture
Exchange nor its Regulation Services Provider (as that term is
defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
Titan Medical Inc.John HargroveChairman and Chief Executive
Officer(416) 548-7522 (ext.
151)john.hargrove@titanmedicalinc.comwww.titanmedicalinc.comInvestor
RelationsBeverly Brooks(416)
482-8889brooks.communications@rogers.com
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From Apr 2023 to Apr 2024